NCT06444165View on ClinicalTrials.gov

Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Lebrikizumab Pen

Injected into a practice pad.

Trial Locations (1)

46240

Concentrics Research, Indianapolis

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06444165 - Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis | Biotech Hunter | Biotech Hunter